EXEL · Exelixis, Inc. · Executive Compensation
$58.41
-0.24 (-0.41%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$14.41B
Shares
247.78M
Volume · Sep 30
3.07M
Avg daily vol (3M)
2.37M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Michael M. Morrissey | President and Chief Executive Officer | $33,239,183 |
| Amy Peterson | Former Executive Vice President, Medical Affairs, and Chief Medical Officer | $11,146,034 |
| Christopher Senner | Executive Vice President and Chief Financial Officer | $10,648,472 |
| Dana T. Aftab | Executive Vice President, Research and Development | $10,547,248 |
| Jeffrey J. Hessekiel | Former Executive Vice President, General Counsel | $8,992,592 |
| Brenda J. Hefti | J.D., Ph.D. Senior Vice President and General Counsel | $4,204,271 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Michael M. Morrissey | President and Chief Executive Officer | $12,732,048 |
| Christopher Senner | Executive Vice President and Chief Financial Officer | $4,680,160 |
| Amy Peterson | Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer | $4,446,015 |
| Jeffrey J. Hessekiel | Executive Vice President, General Counsel | $3,736,716 |
| Dana T. Aftab | Executive Vice President, Discovery and Translational Research and Chief Scientific Officer | $3,616,578 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael M. Morrissey | President and Chief Executive Officer | $16,423,307 |
| Amy Peterson | Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer | $7,378,846 |
| Dana T. Aftab | Executive Vice President, Discovery and Translational Research and Chief Scientific Officer | $5,653,142 |
| Christopher Senner | Executive Vice President and Chief Financial Officer | $4,947,631 |
| Jeffrey J. Hessekiel | Executive Vice President, General Counsel | $4,562,689 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Michael M. Morrissey | President and Chief Executive Officer | $16,877,545 |
| Vicki Goodman | Former Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer | $6,146,000 |
| Christopher Senner | Executive Vice President and Chief Financial Officer | $5,182,270 |
| Jeffrey J. Hessekiel | Executive Vice President, General Counsel | $4,616,110 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Gisela Schwab | Former President, Product Development and Medical Affairs and Chief Medical Officer | $8,869,124 |
| Michael M. Morrissey | President and Chief Executive Officer | $7,530,431 |
| Christopher Senner | Executive Vice President and Chief Financial Officer | $2,457,112 |
| Jeffrey J. Hessekiel | Executive Vice President, General Counsel and Secretary | $2,174,751 |
| Patrick J. Haley | Executive Vice President, Commercial | $2,115,872 |
| Peter Lamb | Ph. D. Executive Vice President, Scientific Strategy and Chief Scientific Officer | $1,962,062 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Michael M. Morrissey | President and Chief Executive Officer | $2,349,812 |
| Patrick J. Haley | Executive Vice President, Commercial | $1,564,653 |
| Gisela Schwab | Former President, Product Development and Medical Affairs and Chief Medical Officer | $1,402,266 |
| Christopher Senner | Executive Vice President and Chief Financial Officer | $1,064,968 |
| Jeffrey J. Hessekiel | Executive Vice President, General Counsel and Secretary | $916,910 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Michael M. Morrissey | President and Chief Executive Officer | $2,132,555 |
| Gisela Schwab | Former President, Product Development and Medical Affairs and Chief Medical Officer | $1,128,482 |
| Christopher Senner | Executive Vice President and Chief Financial Officer | $942,259 |
| Jeffrey J. Hessekiel | Executive Vice President, General Counsel and Secretary | $838,674 |
| Peter Lamb | Executive Vice President, Scientific Strategy and Chief ScientificOfficer | $784,706 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Michael M. Morrissey | President and Chief Executive Officer | $5,064,983 |
| Gisela Schwab | President, Product Development and Medical Affairs and Chief Medical Officer | $2,374,457 |
| Christopher Senner | Executive Vice President and Chief Financial Officer | $2,168,814 |
| General Counsel | — | $2,069,716 |
| Jeffrey J. Hessekiel | Executive Vice President and GeneralCounsel | $2,069,716 |
| Peter Lamb | Executive Vice President, Scientific Strategy and Chief ScientificOfficer | $1,993,567 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Michael M. Morrissey | President and Chief ExecutiveOfficer | $9,439,583 |
| Gisela Schwab | President, Product Development and Medical Affairs and Chief MedicalOfficer | $4,633,578 |
| Chief FinancialOfficer | — | $3,890,358 |
| Peter Lamb | Executive Vice President, Scientific Strategy and Chief ScientificOfficer | $3,392,724 |
| Jeffrey J. Hessekiel | Executive Vice President and GeneralCounsel | $3,196,103 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jack L. Wyszomierski | Director | Appointed | 2026-05-29 |
| Julie Anne Smith | Director | Appointed | 2026-05-29 |
| George Poste, DVM, Ph.D., FRS | Director | Appointed | 2026-05-29 |
| Robert L. Oliver, Jr. | Director | Appointed | 2026-05-29 |
| Stelios Papadopoulos, Ph.D. | Director | Appointed | 2026-05-29 |
| David E. Johnson | Director | Appointed | 2026-05-29 |
| Michael M. Morrissey, Ph.D. | Director | Appointed | 2026-05-29 |
| Tomas J. Heyman | Director | Appointed | 2026-05-29 |
| Maria C. Freire, Ph.D. | Director | Appointed | 2026-05-29 |
| S. Gail Eckhardt, M.D. | Director | Appointed | 2026-05-29 |
| Mary C. Beckerle, Ph.D. | Director | Appointed | 2026-05-29 |
| Brenda Hefti, J.D., Ph.D. | General Counsel | Appointed | 2025-11-07 |
| Jeffrey Hessekiel, J.D. | Executive Vice President and General Counsel | Resigned | 2025-11-07 |
| Dana T. Aftab, Ph.D. | Executive Vice President, Research and Development | Appointed | 2025-08-29 |
| S. Gail Eckhardt, M.D. | Board of Directors | Appointed | 2024-01-08 |
| Mary C. Beckerle, Ph.D. | Board of Directors | Appointed | 2024-01-08 |
| Lance Willsey | Board of Directors | Resigned | 2023-05-08 |
| Peter Lamb | Executive Vice President, Scientific Strategy | Appointed | 2022-12-15 |
Key facts
CIK
939767
CUSIP
30161Q104
13F (30d)
19 filings
15 filers
Visit website
Investor relations